Tânia S Morais

Tânia S Morais
University of Lisbon | UL · Centro de Química Estrutural (CQE @ ciências)

Ph.D

About

52
Publications
4,470
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
780
Citations
Additional affiliations
September 2015 - October 2017
University of Lisbon
Position
  • PhD Student
March 2014 - November 2015
University of Lisbon
Position
  • PostDoc Position

Publications

Publications (52)
Article
Full-text available
Ruthenium complexes are emerging as one of the most promising classes of complexes for cancer therapy. However, their limited aqueous solubility may be the major limitation to their potential clinical application. In view and to contribute to the progress of this field, eight new water-soluble Ru(II) organometallic complexes of general formula [RuC...
Article
Full-text available
The biological properties of sixteen structurally related monoanionic gold (III) bis(dithiolene/diselenolene) complexes were evaluated. The complexes differ in the nature of the heteroatom connected to the gold atom (AuS for dithiolene, AuSe for diselenolene), the substituent on the nitrogen atom of the thiazoline ring (Me, Et, Pr, iPr and Bu), the...
Article
Chemotherapeutic metallodrugs such as cisplatin and its derivatives are among the most widely applied anticancer treatments worldwide. Despite their clinical success, patients suffer from severe adverse effects while subjected to treatment due to platinum's low selectivity for tumour over healthy tissues. Additionally, intrinsic or acquired resista...
Article
Full-text available
Considering our interest in the use of peptides as potential target-specific drugs or as delivery vectors of metallodrugs for various biomedical applications, it is crucial to explore improved synthetic methodologies to accomplish the highest peptide crude purity in the shortest time possible. Therefore, we compared “classical” fluorenylmethoxycarb...
Article
Full-text available
The interaction between human serum transferrin (hTf) and three promising organometallic Ru (II)- (η⁵-C5H5) derived complexes, that have already shown strong in vitro cytotoxicity towards human cancer cell lines, has been investigated using fluorescence spectroscopic techniques. The results suggested that the formation of Ru-hTf systems involves a...
Article
Full-text available
Cisplatin and derivatives are highly effective in the treatment of a wide range of cancer types; however, these metallodrugs display low selectivity, leading to severe side effects. Additionally, their administration often results in the development of chemoresistance, which ultimately results in therapeutic failure. This scenario triggered the stu...
Article
Full-text available
Introduction Au(III) complexes with dithiolene ligands have been used as molecular conductors and magnetic materials [1 Schiødt NC, Bjørnholm T, Bechgaard K, et al. Structural, electrical, magnetic, and optical properties of bis-benzene-1,2-dithiolato-Au(IV) crystals. Phys Rev B. 1996;53(4):1773–1778.[Crossref], [Web of Science ®] , [Google Scholar...
Article
The biomedical application of discrete supramolecular metal-based structures, specifically self-assembled metallacages, is still an emergent field of study. Capitalizing on the knowledge gained in recent years on the development of 3-dimensional (3D) metallacages as novel drug delivery systems and theranostic agents, we explore here the possibility...
Article
Cancer is one of the worst health issues worldwide, representing the second leading cause of death. Current chemotherapeutic drugs face some challenges like the acquired resistance of the tumoral cells...
Article
A new family of eighteen Cu(I) complexes of general formula [Cu(PP)(LL)][BF4], where PP is a phosphane ligand and LL represents an N,O-heteroaromatic bidentate ligand, has been synthesized and fully characterized by classical analytical and spectroscopic methods. Five complexes of this series were also characterized by Single Cristal X-ray diffract...
Article
The anticancer, antimicrobial and antiplasmodial activities of six gold(III) bis(dithiolene) complexes were studied. Complexes (1-6) showed relevant anticancer properties against A2780/A2780cisR ovarian cancer cells (IC50 values of 0.08-2 µM), also being able to overcome cisplatin resistance on A2780cisR cells. Complex 1 also exhibited significant...
Article
In this work we explored the possibility of improving the selectivity of a cytotoxic Ru complex [RuCp(PPh3)(2,2′-bipy)][CF3SO3] (where Cp = η5-cyclopentadienyl) TM34 towards FGFR(+) breast cancer cells. Molecular dynamics (MD) simulations of TM34 in a phosphatidylcholine membrane model pinpointed the cyclopentadienyl group as a favorable derivatiza...
Article
A new family of eight heterobimetallic Cu(I)-dppf complexes of general formula [Cu(dppf)L][BF4] with dppf = 1,1’-bis(diphenylphosphino)ferrocene and L represents N,N-, N,O- and N,S-heteroaromatic bidentate ligands, have been synthesized and fully characterized by classical analytical, spectroscopic and electrochemical methods. The single crystal st...
Article
Background: Ruthenium complexes have been extensively investigated for their prospective value as alternatives to cisplatin. Recently, we reported the in vitro anticancer properties of a family of organometallic ruthenium( II)-cyclopentadienyl complexes and have explored their mechanism of action. Objective: The purpose of this study was to eval...
Article
A family of six phosphane Cu(I) complexes bearing NN, NO and NS bidentate ligands was synthesized. All the compounds were fully characterized by classical analytical and spectroscopic methods and five of them were also characterized by X-ray diffraction studies. All the compounds exhibit high cytotoxicity against the human breast cancer cell line M...
Chapter
The identification of the mode of action of a drug is mandatory for the development of clinically effective chemotherapeutics. Ruthenium complexes hold potential as alternatives to platinum drugs in cancer chemotherapy. In spite of their great importance, their mechanisms of action have not yet been fully elucidated. Inspired by platinum-based drug...
Article
A new family of copper(I) complexes of general formula [Cu(dppe)(NN)]⁺ have been synthesized and fully characterized, with dppe = 1.2-bis(diphenylphosphino)ethane and NN representing several bidentate heteroaromatic ligands: 2,2′-bipy = 2.2′-bipyridine (1), Me2bpy = 4.4′-dimethyl-2,2′-bipyridine (2), dpytz = 3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazin...
Article
Background: Ruthenium-based anti-cancer compounds are proposed as viable alternatives that might circumvent the disadvantages of platinum-based drugs, the only metallodrugs in clinical use for chemotherapy. Organometallic complexes in particular hold great potential as alternative therapeutic agents since their cytotoxicity involves different mode...
Article
Research on the field of metal complexes for the treatment of cancer diseases has attracted increasing interest due to the urgency in finding more efficient and selective treatments. Owing to their wide structural diversity, organometallic complexes appear as potential alternatives to the design of new anticancer candidates. Herein, we review recen...
Article
As part of our efforts to develop organometallic ruthenium compounds bearing activity on both trypanosomatid parasites and tumor cells, a new Ru(II)–cyclopentadienyl clotrimazole complex, [RuCp(PPh3)2(CTZ)](CF3SO3), where Cp = cyclopentadienyl, CTZ = clotrimazole, was synthesized and characterized. The compound was evaluated in vitro on T. cruzi (Y...
Article
Searching for new prospective antitrypanosomal agents, three novel Ru(II)-cyclopentadienyl compounds, [Ru(η(5)-C5H5)(PPh3)L], with HL=bioactive 5-nitrofuryl containing thiosemicarbazones were synthesized and characterized in the solid state and in solution. The compounds were evaluated in vitro on the blood circulating trypomastigote form of Trypan...
Article
Full-text available
A set of structurally related Ru(η(5)-C5H5) complexes with bidentate N,N'-heteroaromatic ligands have been evaluated as prospective metallodrugs, with focus on exploring the uptake and cell death mechanisms and potential cellular targets. We have extended these studies to examine the potential of these complexes to target cancer cell metabolism, th...
Chapter
Organometallic chemistry and particularly organotransition metal complexes have been an intensive area of research which growth was mainly motivated by the impressive achievements in the field of homogeneous catalysis. In fact, the development of catalysis served as foundation for many important industrial processes. Moreover, the fascinating prope...
Chapter
Recent trends in the search of chemotherapeutics agents revealed increasing prominence for ruthenium organometallic complexes. A new family of compounds structured on the so called “piano-stool” geometry based on ‘RuCp’ fragment is here presented. Cytotoxic studies against several human cancer cell lines showed IC50 values in the range of micro and...
Article
Full-text available
The therapeutic usefulness of anticancer agents relies on their ability to kill cancer cells while sparing normal cells and tissues. Ruthenium complexes hold great potential as suitable alternative drugs to the current cisplatin in the treatment of cancer. Our approach in this field has been the study of organoruthenium complexes, [RuII(η5-Cp)] fam...
Article
Four new compounds of general formula [FeCp(dppe)L][CF3SO3] with L=imidazole substituted ligands, and dppe=ethylenebis(diphenylphosphane) have been synthesized and characterized with the aim to evaluate their anticancer properties. The new compounds were fully characterized by spectroscopic and electrochemical methods and the structure of [Fe(η(5)-...
Article
New ferrocenyl derivatives with the general formula FcC(O)L [Fc = (η⁵-C5H5)Fe(η⁵-C5H4)], where L is an aminoquinoline or hydroxyaminoquinoline, have been synthesized for evaluation of their leishmanicidal properties. The compounds were designed with ferrocene coupled to the quinolines by an amide or ester bridge. Ferrocenyl component is intended to...
Article
Full-text available
Previous studies have described promising antitumor activity of an organometallic Ru(II) complex, η5-Cyclopentadienyl(2,2'-bipyridyl)(triphenylphosphane) Ruthenium(II) triflate ([(η5-C5H5)Ru(2,2'-bipyridyl)(PPh3)][CF3SO3]) herein designated as TM34. Its broad spectrum of activity against a panel of human tumor cell lines and high antiproliferative...
Article
Anticancer activity of the new [Ru(ƒÅ5-C5H5)(PPh3)(Me2bpy)][CF3SO3] (Me2bpy = 4,4Œ-dimethyl-2,2Œ-bipyridine) complex was evaluated in vitro against several human cancer cell lines, namely A2780, A2780CisR, HT29, MCF7, MDAMB231 and PC3. Remarkably, the IC50 values, placed in the nanomolar and sub-micromolar range, largely exceeded the activity of...
Article
Ruthenium complexes hold great potential as alternatives to cisplatin in cancer chemotherapy. We present results on the in vitro antitumor activity of an organometallic ‘RuIICp’ complex, [RuIICp(bipy)(PPh3)][CF3SO3], designated as TM34 (PPh3 = triphenylphosphine; bipy = 2,2′-bipyridine), against a panel of human tumor cell lines with different resp...
Article
The gas-phase behaviour of six Ru(II) cyclopentadienyl-derived complexes with N-coordinated ligands, compounds with antitumor activities against several cancer lines, was studied. This was performed with the intent of establishing fragmentation pathways and to determine the Ru-L(N) and Ru-L(P) ligand bond dissociation energies. Such knowledge can b...
Article
Ruthenium complexes hold great potential as alternatives to cisplatin in cancer chemotherapy. We present results on the in vitro antitumor activity of an organometallic 'Ru(II)Cp' complex, [Ru(II)Cp(bipy)(PPh(3))][CF(3)SO(3)], designated as TM34 (PPh(3) = triphenylphosphine; bipy = 2,2'-bipyridine), against a panel of human tumor cell lines with di...
Article
a b s t r a c t New cationic ruthenium(II) complexes with the formula [Ru(h 5 -C 5 H 5)(LL)(1-BuIm)] [Z], with (LL) ¼ 2PPh 3 or DPPE, and Z ¼ CF 3 SO 3 À , PF 6 À , BPh 4 À , have been synthesized and fully characterized. Spectroscopic and electrochemical studies revealed that the electronic properties of the coordinated 1-butylimidazole were clear...
Article
Four ruthenium(II) complexes with the formula [Ru(η(5)-C(5)H(5))(PP)L][CF(3)SO(3)], being (PP = two triphenylphosphine molecules), L = 1-benzylimidazole, ; (PP = two triphenylphosphine molecules), L = 2,2'bipyridine, ; (PP = two triphenylphosphine molecules), L = 4-Methylpyridine, ; (PP = 1,2-bis(diphenylphosphine)ethane), L = 4-Methylpyridine, , w...
Article
A new family of Ru(II) mixed metallocene complexes of the type [Ru(η5-C5H5)(η6-arene)][PF6] has been synthesized and fully characterized by NMR and UV–Vis spectroscopy. X-ray analysis of single crystal was achieved for all the complexes and revealed the presence of two enantiomers expected for planar chirality originated by the η6 coordination of t...
Data
Variation of viscosity with time at constant temperature for complexes [RuCp(PPh3)2(Bzt)][PF6] 3 and [RuCp(PPh3)2(Tvt)][PF6] 4
Article
Full-text available
Four cationic ruthenium(II) complexes with the formula [Ru(eta(5)-C(5)H(5))(PPh(3))(2)](+), with L = 5-phenyl-1H-tetrazole (TzH) 1, imidazole (ImH) 2, benzo[1,2-b;4,3-b'] dithio-phen-2-carbonitrile (Bzt) 3, and [5-(2-thiophen-2-yl)-vinyl]-thiophene-2-carbonitrile] (Tvt) 4 were prepared and characterized in view to evaluate their potentialities as a...
Article
Inhibition of the growth of LoVo human colon adenocarcinoma and MiaPaCa pancreatic cancer cell lines by two new organometallic ruthenium(II) complexes of general formula [Ru(eta(5)-C(5)H(5))(PP) L][CF(3)SO(3)], where PP is 1,2-bis(diphenylphosphino)ethane and L is 1,3,5-triazine (Tzn) 1 or PP is 2x triphenylphosphine and L is pyridazine (Pyd) 2 has...